Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

raztopina za injiciranje - polidokanol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun melsungen ag - povidon, jodirani - dermalna raztopina - povidon, jodirani 75 mg / 1 g - povidon-jod

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun melsungen ag - povidon, jodirani - dermalna raztopina - povidon, jodirani 75 mg / 1 g - povidon-jod

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alkaloid - int d.o.o. - jod - dermalna raztopina/koncentrat za dermalno raztopino - jod 10 mg / 1 ml - povidon-jod

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alkaloid - int d.o.o. - jod - dermalna raztopina - jod 7,5 mg / 1 ml - povidon-jod

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun melsungen ag - povidon, jodirani - dermalna raztopina - povidon, jodirani 7,5 mg / 1 g - povidon-jod

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun melsungen ag - povidon, jodirani - dermalna raztopina - povidon, jodirani 75 mg / 1 g - povidon-jod

Evropska unija - slovenščina - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistična fibroza - drugi proizvodi dihal - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Evropska unija - slovenščina - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cistična fibroza - drugi proizvodi dihal - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 in 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 in 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gedeon richter plc. - dienogest; etinilestradiol - filmsko obložena tableta - dienogest 2 mg / 1 tableta  etinilestradiol0,03 mg / 1 tableta; etinilestradiol 0,03 mg / 1 tableta - dienogest in etinilestradiol